TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells

Cellular and Molecular Immunology

Volumn 11, Issue 2, 2014, Pages 150-159

  Fang, Hongliang ^a   Ang, Bing ^b   Xu, Xinyun ^c   Huang, Xiaohui ^b   Wu, Yanfeng ^b   Sun, Yanping ^c   Wang, Wenying ^b   Li, Nan ^b   Cao, Xuetao ^a,b   Wan, Tao ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; DAMPs; Dendritic cells; Immunotherapy; TLR4

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; FLUOROURACIL; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; HLA DR ANTIGEN; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OXALIPLATIN; RANTES; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL ACTIVATION; CELL DEATH; CELL MATURATION; CELL STRESS; CELLULAR IMMUNITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DANGER ASSOCIATED MOLECULAR PATTERN; DENDRITIC CELL; DRUG RESPONSE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DEPLETION; SERUM; UPREGULATION;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CELL DIFFERENTIATION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOKINES; DENDRITIC CELLS; DNA DAMAGE; FLUOROURACIL; HMGB1 PROTEIN; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 4; TUMOR BURDEN; VACCINATION;

EID: 84895508673     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2013.59     Document Type: Article

References (44)

1. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25: 1247-1254
2. Landry JC, Feng Y, Cohen SJ, Staley CA 3rd, Whittington R, Sigurdson ER et al. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer 2013; 119: 1521-1527
3. Nace G, Evankovich J, Eid R, Tsung A. Dendritic cells and damageassociated molecular patterns: Endogenous danger signals linking innate and adaptive immunity. J Innate Immun 2012; 4: 6-15
4. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860-875
5. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013; 133: 624-636
6. Krysko O, Løve Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis 2013; 4: 628-631
7. He Y, Zha J, Wang Y, Liu W, Yang X, Yu P. Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res 2013; 73: 629-639
8. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012; 72: 3290-3301
9. Fu Q, Wu Y, Yan F, Wang N, Wang W, Cao X et al. Efficient induction of a Her2-specific anti-tumor response by dendritic cells pulsed with a HSP70L1-Her2(341-456) fusion protein. Cell Mol Immunol 2011; 8: 424-432
10. Hee Lee J, Park MS, Hwang JE, Cho SH, Bae WK, Shim HJ et al. Dendritic cell-based immunotherapy for colon cancer using an HLAA &z.ast; 0201-restricted cytotoxic T-lymphocyte epitope from tumorassociated antigen 90K. Cell Mol Immunol 2013; 10: 275-282
11. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-277
12. Ju DW, Tao Q, Lou G, Bai M, He L, Yang Y et al. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res 2001; 61: 3735-3740
13. Zhang LH, Pan JP, Yao HP, SunWJ, Xia DJ, Wang QQ et al. Intrasplenic transplantation of IL-18 gene-modified hepatocytes: An effective approach to reverse hepatic fibrosis in schistosomiasis through induction of dominant Th1 response. Gene Ther 2001; 8: 1333-1342
14. Shurin GV, Ma Y, Shurin MR. Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron 2013; 6: 159-167
15. Demoulin S, Herfs M, Delvenne P, Hubert P. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: Insight into the molecular mechanisms. J Leukoc Biol 2013; 93: 343-352
16. Fang H, Wu Y, Huang X, Wang W, Ang B, Cao X et al. Toll-like receptor 4 (TLR4) is essential for HSP70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response. J Biol Chem 2011; 286: 30393-30400
17. Thuringer D, Hammann A, Benikhlef N, Fourmaux E, Bouchot A, Wettstein G et al. Transactivation of the epidermal growth factor receptor by heat shock protein 90 via Toll-like receptor 4 contributes to the migration of glioblastoma cells. J Biol Chem 2011; 286: 3418-3428
18. Gong J, Zhu B, Murshid A, Adachi H, Song B, Lee A et al. T cell activation by heat shock protein 70 vaccine requires TLR signaling and scavenger receptor expressed by endothelial cells-1. J Immunol 2009; 183: 3092-3098
19. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059
20. Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM et al. Tolllike receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010; 16: 413-419
21. Gasse P, Riteau N, Charron S, Girre S, Fick L, Pé trilli V et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009; 179: 903-913
22. Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology 2012; 1: 271-278
23. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749-3752
24. Wan T, Zhou X, Chen G, An H, Chen T, ZhangWet al. Novel heat shock protein HSP70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant. Blood 2004; 103: 1747-1754
25. Liu X, Zhan Z, Li D, Xu L, Ma F, Zhang P et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 2011; 12: 416-424
26. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189: 1777-1782
27. Fredly H, Ersvær E, Gjertsen BT, Bruserud O. Immunogenic apoptosis in human acute myeloid leukemia (AML): Primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 2011; 25: 1549-1556
28. Sevko A, Sade-FeldmanM, Kanterman J,Michels T, Falk CS, Umansky L et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol 2013; 133: 1610-1619
29. TonguM, Harashima N, Yamada T, Harada T, Harada M. Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother 2010; 59: 769-777
30. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73
31. Andre F, Dieci MV, Dubsky P, Sotiriou C, Curigliano G, Denkert C et al. Molecular pathways: Involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res 2013; 19: 28-33
32. Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P et al. Immunogenic cell death biomarkersHMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer 2013; 132: 2349-2358
33. Date K, Hall J, Greenman J, Maraveyas A, Madden LA. Tumour and microparticle tissue factor expression and cancer thrombosis. Thromb Res 2013; 131: 109-115
34. Tang K, Zhang Y, Zhang H, Xu P, Liu J, Ma J et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun 2012; 3: 1282
35. Guo Z, Zhang M, Tang H, Cao X. Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines. Blood 2005; 106: 2033-2041
36. Guo J, Zhang M, Wang B, Yuan Z, Guo Z, Chen T et al. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Int J Cancer 2003; 103: 212-220
37. Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E et al. Macrophagederived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 2002; 9: 793-803
38. Li DY, Gu C, Min J, Chu ZH, Ou QJ. Maturation induction of human peripheral blood mononuclear cell-derived dendritic cells. Exp Ther Med 2012; 4: 131-134
39. Zhang L, Mi J, Yu Y, Yao H, Chen H, Li M et al. IFN-gamma gene therapy by intrasplenic hepatocyte transplantation: A novel strategy for reversing hepatic fibrosis in Schistosoma japonicum-infected mice. Parasite Immunol 2001; 23: 11-17
40. WuY, Wan T, Zhou X, Wang B, Yang F, LiN et al. HSP70-like protein 1 fusion protein enhances induction of carcinoembryonic antigenspecific CD81 CTL response by dendritic cell vaccine. Cancer Res 2005; 65: 4947-4954
41. Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Häcker H et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276: 31332-31339
42. Asea A. Heat shock proteins and toll-like receptors. Handb Exp Pharmacol 2008; 183: 111-127
43. Todorova J, Pasheva E. High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncol Lett 2012; 3: 214-218
44. Rouhiainen A, Kuja-Panula J, Tumova S, Rauvala H. RAGE-mediated cell signaling. Methods Mol Biol 2013; 963: 239-263